In briefBMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4728 (Published 26 July 2011) Cite this as: BMJ 2011;343:d4728
Benefits of varenicline outweigh risks: The European Medicines Agency has said that the slightly increased risk of cardiovascular events associated with varenicline (Champix) reported in a recent meta-analysis (BMJ 2011;343:doi:10.1136/bmj.d4428) does not outweigh the benefits of the drug in helping people to stop smoking. The agency has asked Pfizer, which markets Champix, to submit changes to the medicine’s product information to provide more information on cardiovascular events.
WHO urges ban of commercial blood tests in TB diagnosis: The World Health …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial